Cardiovascular protection of magnolol: cell-type specificity and dose-related effects

Journal of Biomedical Science

Chuang-Ye Hong¹  Jennifer Hui-Chun Ho² 

[1] Department of Medicine, Wan Fang Hospital, Taipei Medical University, 111, Sec 3, Hsing-Long Rd, Taipei, 116, Taiwan;Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA, USA

关键词: Antioxidant;    Inflammation;    Smooth muscle cells;    Vascular endothelial cells;    Cardiomyocytes;    Magnolol;   

Others  :  824698
DOI  :  10.1186/1423-0127-19-70

 received in 2012-04-13, accepted in 2012-06-26,  发布年份 2012

【 摘 要 】

Magnolia officinalis has been widely used in traditional Chinese medicine. Magnolol, an active component isolated from Magnolia officinalis, is known to be a cardiovascular protector since 1994. The multiplex mechanisms of magnolol on cardiovascular protection depends on cell types and dosages, and will be reviewed and discussed in this article. Magnolol under low and moderate dosage possesses the ability to protect heart from ischemic/reperfusion injury, reduces atherosclerotic change, protects endothelial cell against apoptosis and inhibits neutrophil-endothelial adhesion. The moderate to high concentration of magnolol mainly acts on smooth muscle cells and platelets. Magnolol induces apoptosis in vascular smooth muscle cells at moderate concentration and inhibits proliferation at moderate and high concentration. High concentration of magnolol also abrogates platelet activation, aggregation and thrombus formation. Magnolol also serves as an smooth muscle relaxant only upon the high concentration. Oral intake of magnolol to reach the therapeutic level for cardiovascular protection is applicable, thus makes magnolol an agent of great potential for preventing cardiovascular diseases in high-risk patients.

【 授权许可】

   
2012 Ho and Hong; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wu YT, Lin LC, Tsai TH: Simultaneous determination of honokiol and magnolol in Magnolia officinalis by liquid chromatography with tandem mass spectrometric detection. Biomed Chromatogr 2006, 20:1076-1081.
• [2]Liu L, Wu X, Fan L, Chen X, Hu Z: Separation and determination of honokiol and magnolol in herbal medicines by flow injection-capillary electrophoresis. Anal Bioanal Chem 2006, 384:1533-1539.
• [3]Fried LE, Arbiser JL: Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 2009, 11:1139-1148.
• [4]Amblard F, Govindarajan B, Lefkove B, Rapp KL, Detorio M, Arbiser JL, Schinazi RF: Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. Bioorg Med Chem Lett 2007, 17:4428-4431.
• [5]Srinivas J, Reddy Doma M, Singh PP, Kumar S, Malik F, Sharma A, Khan IA, Qazi GN, Kumar HM: Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds. Eur J Med Chem 2012, 51:35-41.
• [6]Wang Y, Li CY, Lin IH, Lee AR, Hu MK: Synthesis and radical scavenging of novel magnolol derivatives. J Pharm Pharmacol 2002, 54:1697-1703.
• [7]Ai J, Wang X, Nielsen M: Honokiol and magnolol selectively interact with GABAA receptor subtypes in vitro. Pharmacology 2001, 63:34-41.
• [8]Chen CR, Tan R, Qu WM, Wu Z, Wang Y, Urade Y, Huang ZL: Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice. Br J Pharmacol 2011, 164:1534-1546.
• [9]Han SJ, Bae EA, Trinh HT, Yang JH, Youn UJ, Bae KH, Kim DH: Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors. Biol Pharm Bull 2007, 30:2201-2203.
• [10]Ho KY, Tsai CC, Chen CP, Huang JS, Lin CC: Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res 2001, 15:139-141.
• [11]Seo JU, Kim MH, Kim HM, Jeong HJ: Anticancer potential of magnolol for lung cancer treatment. Arch Pharm Res 2011, 34:625-633.
• [12]Lo YC, Teng CM, Chen CF, Chen CC, Hong CY: Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol 1994, 47:549-553.
• [13]Kong CW, Tsai K, Chin JH, Chan WL, Hong CY: Magnolol attenuates peroxidative damage and improves survival of rats with sepsis. Shock 2000, 13:24-28.
• [14]Clark AM, El-Feraly FS, Li WS: Antimicrobial activity of phenolic constituents of Magnolia grandiflora L. J Pharm Sci 1981, 70:951-952.
• [15]Esumi T, Makado G, Zhai H, Shimizu Y, Mitsumoto Y, Fukuyama Y: Efficient synthesis and structure-activity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg Med Chem Lett 2004, 14:2621-2625.
• [16]Hong CY, Huang SS, Tsai SK: Magnolol reduces infarct size and suppresses ventricular arrhythmia in rats subjected to coronary ligation. Clin Exp Pharmacol Physiol 1996, 23:660-664.
• [17]Tsai SK, Huang SS, Hong CY: Myocardial protective effect of honokiol: an active component in Magnolia officinalis. Planta Med 1996, 62:503-506.
• [18]Tsai SK, Huang CH, Huang SS, Hung LM, Hong CY: Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Pharmacology 1999, 59:227-233.
• [19]Huang CH, Hong CY, Tsai SK, Lai ST, Weng ZC, Chih CL, Hsieh YH: Intravenous pretreatment with magnolol protects myocardium against stunning. Planta Med 2000, 66:516-520.
• [20]Lee YM, Hsiao G, Chen HR, Chen YC, Sheu JR, Yen MH: Magnolol reduces myocardial ischemia/reperfusion injury via neutrophil inhibition in rats. Eur J Pharmacol 2001, 422:159-167.
• [21]Huang CH, Hong CY, Tsai SK, Lai ST: Effect of magnolol on coronary vascular resistance in rabbits: measurement with pulsed Doppler velocimetry. J Formos Med Assoc 2000, 99:554-558.
• [22]Jin YC, Kim KJ, Kim YM, Ha YM, Kim HJ, Yun UJ, Bae KH, Kim YS, Kang SS, Seo HG, Lee JH, Chang KC: Anti-apoptotic effect of magnolol in myocardial ischemia and reperfusion injury requires extracellular signal-regulated kinase1/2 pathways in rat in vivo. Exp Biol Med (Maywood) 2008, 233:1280-1288.
• [23]Liou JY, Chen YL, Loh SH, Chen PY, Hong CY, Chen JJ, Cheng TH, Liu JC: Magnolol depresses urotensin-II-induced cell proliferation in rat cardiac fibroblasts. Clin Exp Pharmacol Physiol 2009, 36:711-716.
• [24]Chen YL, Lin KF, Shiao MS, Chen YT, Hong CY, Lin SJ: Magnolol, a potent antioxidant from Magnolia officinalis, attenuates intimal thickening and MCP-1 expression after balloon injury of the aorta in cholesterol-fed rabbits. Basic Res Cardiol 2001, 96:353-363.
• [25]Chen JH, Wu CC, Hsiao G, Yen MH: Magnolol induces apoptosis in vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 2003, 368:127-133.
• [26]Wu CH, Chen CW, Chen HC, Chang WC, Shu MJ, Hung JS: Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation. J Pharmacol Sci 2005, 99:392-399.
• [27]Kim HM, Bae SJ, Kim DW, Kim BK, Lee SB, Lee US, Kim CH, Moon SK: Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int Immunopharmacol 2007, 7:1083-1091.
• [28]Watanabe K, Watanabe HY, Goto Y, Yamamoto N, Yoshizaki M: Studies on the active principles of magnolia bark. Centrally acting muscle relaxant activity of magnolol and hōnokiol. Jpn J Pharmacol 1975, 25:605-607.
• [29]Watanabe H, Watanabe K, Hagino K: Chemostructural requirement for centrally acting muscle relaxant effect of magnolol and honokiol, neolignane derivatives. J Pharmacobiodyn 1983, 6:184-190.
• [30]Teng CM, Yu SM, Chen CC, Huang YL, Huang TF: EDRF-release and Ca + (+)-channel blockade by magnolol, an antiplatelet agent isolated from Chinese herb Magnolia officinalis, in rat thoracic aorta. Life Sci 1990, 47:1153-1161.
• [31]Ko CH, Chen HH, Lin YR, Chan MH: Inhibition of smooth muscle contraction by magnolol and honokiol in porcine trachea. Planta Med 2003, 69:532-536.
• [32]Lu YC, Chen HH, Ko CH, Lin YR, Chan MH: The mechanism of honokiol-induced and magnolol-induced inhibition on muscle contraction and Ca2+ mobilization in rat uterus. Naunyn Schmiedebergs Arch Pharmacol 2003, 368:262-269.
• [33]Ou HC, Chou FP, Sheu WH, Hsu SL, Lee WJ: Protective effects of magnolol against oxidized LDL-induced apoptosis in endothelial cells. Arch Toxicol 2007, 81:421-432.
• [34]Sheu ML, Chiang CK, Tsai KS, Ho FM, Weng TI, Wu HY, Liu SH: Inhibition of NADPH oxidase-related oxidative stress-triggered signaling by honokiol suppresses high glucose-induced human endothelial cell apoptosis. Free Radic Biol Med 2008, 44:2043-2050.
• [35]Son HJ, Lee HJ, Yun-Choi HS, Ryu JH: Inhibitors of nitric oxide synthesis and TNF-alpha expression from Magnolia obovata in activated macrophages. Planta Med 2000, 66:469-471.
• [36]Wang JP, Chen CC: Magnolol induces cytosolic-free Ca2+ elevation in rat neutrophils primarily via inositol trisphosphate signalling pathway. Eur J Pharmacol 1998, 352:329-334.
• [37]Shen YC, Sung YJ, Chen CF: Magnolol inhibits Mac-1 (CD11b/CD18)-dependent neutrophil adhesion: relationship with its antioxidant effect. Eur J Pharmacol 1998, 343:79-86.
• [38]Wang JP, Lin PL, Hsu MF, Chen CC: Possible involvement of protein kinase c inhibition in the reduction of phorbol ester-induced neutrophil aggregation by magnolol in the rat. J Pharm Pharmacol 1998, 50:1167-1172.
• [39]Chen YH, Lin SJ, Ku HH, Shiao MS, Lin FY, Chen JW, Chen YL: Salvianolic acid B attenuates VCAM-1 and ICAM-1 expression in TNF-alpha-treated human aortic endothelial cells. J Cell Biochem 2001, 82:512-521.
• [40]Chen YH, Lin SJ, Chen JW, Ku HH, Chen YL: Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits. Br J Pharmacol 2002, 135:37-47.
• [41]Chen SC, Chang YL, Wang DL, Cheng JJ: Herbal remedy magnolol suppresses IL-6-induced STAT3 activation and gene expression in endothelial cells. Br J Pharmacol 2006, 148:226-232.
• [42]Teng CM, Chen CC, Ko FN, Lee LG, Huang TF, Chen YP, Hsu HY: Two antiplatelet agents from Magnolia officinalis. Thromb Res 1988, 50:757-765.
• [43]Tsai TH, Tsai WJ, Chou CJ, Chen CF: Magnolol inhibits collagen-induced platelet serotonin release. Thromb Res 1995, 78:265-270.
• [44]Yamazaki R, Sugatani J, Fujii I, Kuroyanagi M, Umehara K, Ueno A, Suzuki Y, Miwa M: Development of a novel method for determination of acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine acetyltransferase activity and its application to screening for acetyltransferase inhibitors, Inhibition by magnolol and honokiol from Magnoliae cortex. Biochem Pharmacol 1994, 47:995-1006.
• [45]Tsai TH, Chou CJ, Chen CF: Disposition of magnolol after intravenous bolus and infusion in rabbits. Drug Metab Dispos 1994, 22:518-521.
• [46]Tsai TH, Chou CJ, Chen CF: Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection. J Pharm Pharmacol 1996, 48:57-59.
• [47]Wu X, Chen X, Hu Z: High-performance liquid chromatographic method for simultaneous determination of honokiol and magnolol in rat plasma. Talanta 2003, 59:115-121.
• [48]Yu Q, Xiang J, Tang W, Liang M, Qin Y, Nan F: Simultaneous determination of the 10 major components of Da-Cheng-Qi decoction in dog plasma by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:2025-2031.
• [49]Tsai TH, Chou CJ, Lee TF, Wang LCH, Chen CF: Pharmacokinetic and pharmacodynamic studies of magnolol after oral administration in rats. Pharmaceut Sci 1996, 2:191-193.
• [50]Lin SP, Tsai SY, Lee Chao PD, Chen YC, Hou YC: Pharmacokinetics, bioavailability, and tissue distribution of magnolol following single and repeated dosing of magnolol to rats. Planta Med 2011, 77:1800-1805.
• [51]Homma M, Oka K, Taniguchi C, Niitsuma T, Hayashi T: Systematic analysis of post-administrative saiboku-to urine by liquid chromatography to determine pharmacokinetics of traditional Chinese medicine. Biomed Chromatogr 1997, 11:125-131.
• [52]Li N, Song Y, Zhang W, Wang W, Chen J, Wong AW, Roberts A: Evaluation of the in vitro and in vivo genotoxicity of magnolia bark extract. Regul Toxicol Pharmacol 2007, 49:154-159.
• [53]Liu Z, Zhang X, Cui W, Zhang X, Li N, Chen J, Wong AW, Roberts A: Evaluation of short-term and subchronic toxicity of magnolia bark extract in rats. Regul Toxicol Pharmacol 2007, 49:160-171.
• [54]Yang HY, Chen CF: Pharmacology and toxicology of herbal medicine: subacute toxicity of commonly used Chinese drugs. J Toxicol Sci 1998, 23(Suppl 2):229-233.
• [55]Oikawa T, Ito G, Hoshino T, Koyama H, Hanawa T: Hangekobokuto (Banxia-houpo-tang), a Kampo Medicine that Treats Functional Dyspepsia. Evid Based Complement Alternat Med 2009, 6:375-378.
• [56]Garrison R, Chambliss WG: Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med 2006, 12:50-54.
• [57]Ha T, Liu L, Kelley J, Kao R, Williams D, Li C: Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid Redox Signal 2011, 15:1875-1893.
• [58]Kukreja RC, Yin C, Salloum FN: MicroRNAs: new players in cardiac injury and protection. Mol Pharmacol 2011, 80:558-564.
• [59]Machado NG, Alves MG, Carvalho RA, Oliveira PJ: Mitochondrial involvement in cardiac apoptosis during ischemia and reperfusion: can we close the box? Cardiovasc Toxicol 2009, 9:211-227.
• [60]Badimon L, Martínez-González J, Llorente-Cortés V, Rodríguez C, Padró T: Cell biology and lipoproteins in atherosclerosis. Curr Mol Med 2006, 6:439-456.
• [61]Orr AW, Hastings NE, Blackman BR, Wamhoff BR: Complex regulation and function of the inflammatory smooth muscle cell phenotype in atherosclerosis. J Vasc Res 2010, 47:168-180.
• [62]Libby P, Ridker PM, Hansson GK: Leducq Transatlantic Network on Atherothrombosis: Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009, 54:2129-2138.